Chronic obstructive pulmonary disease Inhaled corticosteroid dose associated Pseudomonas aeruginosa infection severe COPD Hanaa Shafiek12 Javier Verdú2 Amanda Iglesias34 Lluisa Ramon Clar2 Nuria Toledo Pons2 Carla Lopez Causape45 Carlos Juan45 Pablo Fraile Ribot45 Antonio Oliver45 Borja G Cosio 2 To cite Shafiek H Verdú J Iglesias A et al Inhaled corticosteroid dose associated Pseudomonas aeruginosa infection severe COPD BMJ Open Resp Res 20218e001067 doi101136 bmjresp2021001067 Additional supplemental material published online To view visit journal online http dx doi org 10 1136 bmjresp 2021 001067 Received 16 August 2021 Accepted 23 September 2021 Authors employers 2021 Re use permitted CC BY NC No commercial use See rights permissions Published BMJ 1Department Chest Diseases Alexandria University Faculty Medicine Alexandria Egypt 2Department Respiratory Medicine Hospital Universitario Son Espases Palma Mallorca Spain 3CIBERES Instituto Salud Carlos III Madrid Spain 4Instituto Investigación Sanitaria las Islas Baleares IdISBa Palma Mallorca Spain 5Department Clinical Microbiology Hospital Universitario Son Espases Palma Mallorca Spain Correspondence Professor Borja G Cosio borja cosio ssib es ABSTRACT Introduction Patients chronic obstructive pulmonary disease COPD frequent exacerbations ExCOPD commonly treated inhaled corticosteroids ICS risk infections caused potential pathogenic bacteria PPB including Pseudomonas aeruginosa PsA Objectives To investigate association use ICS PsA infection ExCOPD Methods Casecontrol study longitudinal follow recruited ExCOPD hospitalisation exacerbation 2012 2020 Patients isolation PsA COPD PsA sputum admission follow compared PPB Clinical functional characteristics DDD use ICS survival evaluated Cox regression analysis performed evaluate risk factors associated PsA infection mortality Results 358 patients 78 male mean age 739 years enrolled followed median 4 years IQR38 173 patients 483 positive culture PsA COPD PsA frequent exacerbations severe airflow limitation higher mortality 694 vs 465 p0001 There differences use ICS groups dose ICS significantly higher COPD PsA median 500 µg fluticasone propionate equivalents IQR2501000 vs 400 µg IQR2001000 p0007 Blood eosinophil count BEC different ICS users non users In multivariate analysis dose ICS independent risk factor PsA infection mortality ICS use Conclusions ICS dose use risk factor PsA infection patients severe COPD regardless BEC INTRODUCTION Chronic obstructive pulmonary disease frequent exacerbations ExCOPD specific clinical phenotype associated progressive decline lung function higher mortality morbidity1 2 About 50 acute COPD exacerbations AECOPD caused potential pathogenic bacteria PPB infections isolated sputum bronchial secretions cultures35 KEY MESSAGES Are inhaled corticosteroids ICS use potential risk factor Pseudomonas aeruginosa infection frequent exacerbator severe chronic obstructive pulmonary disease COPD The use high dose ICS severe patients COPD frequent exacerbations associated Pseudomonas aeruginosa infection poorer sur vival regardless blood eosinophil count effect observed low medium doses These findings help clinicians modify daily practice decision pre scribing ICS patients severe COPD especial ly dose ICS Haemophilus influenzae Streptococcus pneu moniae Moraxella catarrhalis commonly isolated PPB3 4 Other Gram negative bacteria specifically Pseudomonas aeruginosa PsA Stenotrophomonas malto philia associated severe exac erbations debilitated patients6 7 PsA isolation AECOPD hospitalisations associated greater degree airway obstruction use systemic corticosteroids poorer lung function previous isolation PsA previous hospital admission810 Further PsA linked increased airway inflammation patients COPD11 mortality12 Inhaled corticosteroids ICS indicated treatment ExCOPD especially blood eosinophil count BEC higher 300 cellsµL13 14 ICS therapy associated adverse effects espe cially risk pneumonia15 raises debate prescription ICS patients infectious exacerbations Further long term use ICS associated increased bacterial load airway modification microbiome compo sition16 The relationship ICS use risk PsA infection clinical 1 Shafiek H et al BMJ Open Resp Res 20218e001067 doi101136bmjresp2021001067 Open access consequences patients COPD stab lished modify indication treatment patients ExCOPD caused PsA Accordingly study aimed 1 investigate association use ICS PsA infection ExCOPD 2 identify risk factors associated PsA infection ExCOPD population 3 study risk factors associated mortality ExCOPD METHODS Study design ethics Casecontrol recruited patients study confirmed diagnosis COPD based Global Initiative Chronic Obstructive Lung Diseases GOLD criteria history frequent exacerbations hospital isation AECOPD13 The study conducted tertiary teaching hospital 2012 2020 All patients regularly followed discharged ordinary outpatient respiratory clinics integrated care programme ExCOPD running hospital10 maximum 8 years All patients signed written informed consent Patient public involvement It appropriate possible involve patients public design conduct reporting dissemi nation plans research Population All patients diagnosis COPD according GOLD criteria13 hospitalisation AECOPD history 2 exacerbations year able produce sputum sample admission follow living area influence hospital included study Patients COPD growing PsA sputum culture taken admission follow single isolated microorganism mixed PPB considered cases COPD PsA group Patients cultures resulting PPB different PsA growing usual respiratory flora considered controls COPD non PsA group Further patients follow invalid sputum sample unable produce sputum previous sputum sample posi tive PsA considered COPD non PsA Patients COPD non respiratory comorbidity including deteriorative cognitive function psychiatric illness affected mental capacity substantially affected prognosis disease excluded study scan hospitalisation follow Detailed drug historynamely long acting ß2 agonist long inhaled acting antimuscarinic bronchodilators ICS including type ICS dose modification study durationwas taken All doses ICS calculated fluticasone propionate equivalents 100250 µg daily dose considered low dose 400500 µg medium dose 1000 µg high dose17 All acute exacerbations defined GOLD guide lines13 requiring hospital contact outpatients requiring emergency visit new hospitalisation recorded AECOPD treated according GOLD guide lines13 The patients followed discharge hospital initially 2 weeks later 3 6 months scheduled visits Sputum culture A sputum sample taken microbiological evalua tion hospitalisation AECOPD patient admitted follow patient previous positive culture PPB presentation symptoms AECOPD Respiratory samples collected sterile containers 24 hours admission hospital isation follow presenting hospital outpatient respiratory clinics Samples transferred 2 hours microbiological laboratory Gram staining bacterial culture Sputum samples tested viability culture according Murray Washington criteria18 In case non viable sample sputum sample recollected Patients unable valid sputum sample hospital isation bronchoscopy performed bronchial aspi rate collected A sputum bacterial load 106 bron chial aspirate bronchial load 104 colony forming units mL considered significant The identified micro organisms classified PsA PPB including Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis methicillin susceptible methicillin resistant Staphylococcus aureus Gram negative bacilli Other micro organisms Streptococcus viridans Staphylococcus epidermidis Candida spp considered non PPB Variables outcomes ExCOPD mortality recorded patient follow The higher value blood eosinophils recorded New episodes PsA infection PPB infec tion pneumonia hospitalisation follow recorded Further use ICS dose recorded follow patients analysis Procedures All patients underwent clinical evaluation pulmonary function testing chest X ray chest CT rule bronchiectasis suspected 98 underwent CT Statistical analysis Quantitative data presented meanSD median IQR according normal distribution qual itative data presented number percentage 2 Shafiek H et al BMJ Open Resp Res 20218e001067 doi101136bmjresp2021001067 Open access Unpaired Students t test Mann Whitney U test χ2 tests appropriate Spearman correlation coefficient study collinearity BEC ICS PsA infection Bivariate multivariate Cox regression analysis evaluate hazard factors associated PsA infection mortality Cox regression analysis considered based fact change ICS use doseas covariateover follow duration study A multivariate model built basis prescreening univariable significance clinical relevance covariates initial comparisons according presence absence PsA infection The covariates introduced model manually multiple multivariate models evaluated The multivariate model best overall goodness fit chosen HR 95 CI shown In Cox regression models fluticasone propionate equivalents ICS doses considered groups patients Kaplan Meier survival analysis plotted order identify survival probability ICS users follow A tailed p005 considered statistically significant SPSS package V220 IBM analyses Inhaled corticosteroids The use ICS different patients COPD PsA group compared COPD non PsA 879 vs 827 p0170 table 1 The daily dose ICS significantly higher COPD PsA group compared COPD non PsA infection median 500 IQR2501000 vs 400 IQR2001000 µg day fluticasone propionate equivalents respectively p0007 table 1 Fluticasone propionate frequently ICS followed budesonide p0003 table 1 On follow statistically signifi reduction daily ICS dose groups compared doses time enrolment study median 400 IQR1001000 vs 500 IQR2001000 µgday fluticasone propionate equiva lents p00001 online supplemental figure S1 We statistically significant difference COPD PsA COPD non PsA groups incidence pneumonia p0118 table 1 Further association use ICS pneumonia p0858 data shown Moreover BEC different ICS users non users 27083184 vs 25252635 p0692 RESULTS Patient characteristics The current study enrolled 358 patients COPD discharge AECOPD followed median 4 years IQR38 173 patients 483 sputum growing PsA Table 1 shows base line clinical characteristics studied COPD population classified according presence COPD PsA absence PsA infection COPD non PsA Male constituted majority COPD PsA COPD non PsA groups 867 697 respectively p0001 table 1 There statistically significant difference age smoking history associated comorbidities modified medical research council mMRC dyspnoea scale history AECOPD pneumonia p005 table 1 frequent exacerbations lower forced expiratory volume 1 s FEV1 predicted detected COPD PsA group p0001 0036 respectively table 1 The majority COPD PsA group GOLD III IV 468 281 respectively p0008 table 1 Bronchiectasis frequently associated PsA infection 26 vs 114 p0001 table 1 COPD PsA group frequently detected PPB compared COPD non PsA group 449466 vs 066102 respectively p0001 table 1 Inhaled antibi otics colistin tobramycin frequently prescribed COPD PsA group p001 data shown Systemic corticosteroids courses administrated AECOPD significantly frequent PsA infection non PsA group 768714 vs 539550 p0001 table 1 Further mortality higher COPD PsA 8 years follow 694 vs 465 p0001 table 1 Correlations PsA infection positively correlated BEC r0381 p0001 online supplemental table S2 ICS dose r0107 p0042 online supplemental table S2 correlation PsA infection ICS use r 0008 p0884 online supplemental table S2 Further correlation BEC ICS dose BEC ICS use p005 online supplemental table S2 Regression survival analysis In bivariate cox regression analysis ICS use type ICS use systemic corticoster oids AECOPD 3 courses follow duration independent risk factors associated PsA infection patients COPD p005 online supplemental table S1 dose ICS statistically significant independent risk factor PsA infection OR 115 95 CI 104 128 p0009 online supplemental table S1 Similarly ICS use risk factor development pneumonia HR 128 95 CI 083 198 p0270 dose ICS signifi weak risk factor development pneumonia HR 112 95 CI 10 125 p0043 Moreover daily dose ICS use signif icant risk factor associated PsA infection multivar iate Cox regression analysis HR 126 95 CI 101 157 p0040 table 2 correction age mMRC dyspnoea scale degree airway obstruction based GOLD classification use systemic corti costeroids AECOPD cumulative hazard 90 acquiring PsA infection case high ICS dose figure 1 follow Shafiek H et al BMJ Open Resp Res 20218e001067 doi101136bmjresp2021001067 3 Open access Table 1 Baseline characteristics COPD population classified according PsA infection study duration 20122020 COPD non PsA Sig n185 517 P value Character Age Gender Male Female Smoking status Active smoker Ex smoker Non smoker Smoking index Comorbidities Associated bronchiectasis No exacerbations Associated pneumonia mMRC dyspnoea scale No cultures PBB Baseline pulmonary function testing FEV1 predicted DLCO predicted RV GOLD classification I II III IV Medications ICS Type ICS Fluticasone propionate Fluticasone furoate Beclomethasone Budesonide Dose ICS LAMA LABA Theophylline Roflumilast Courses systemic corticosteroids Mortality COPD PsA n173 483 7363843 150 867 23 133 40 231 132 763 1 06 64143042 171 994 45 26 662591 82 474 253084 449466 4134177 41461721 198646192 10 58 33 193 80 468 48 281 7329971 129 697 56 303 48 262 136 732 1 05 59943049 181 978 21 114 408361 76 411 244077 066102 4521653 4391916 196936156 6 33 62 344 77 428 35 194 152 879 153 827 108 624 6 35 10 58 28 162 78 422 14 76 22 119 39 211 500 2501000 400 2001000 158 913 168 971 28 162 8 46 768714 120 694 174 941 177 957 34 184 5 27 539550 86 465 0729 0001 0794 0207 0204 0001 0001 0118 0289 0001 0036 0301 0841 0008 017 0003 0007 0306 0558 0584 0331 0001 0001 Significant p005 Bronchiectasis diagnosed based CT taken hospitalisation follow patients Positive sputum bronchial aspirate culture potential pathological bacteria Fluticasone propionate equivalents daily dose COPD chronic obstructive pulmonary disease DLCO diffusion capacity carbon monoxide FEV1 forced expiratory volume 1 s ICS inhaled corticosteroids LABA long acting beta agonist LAMA long acting muscarinic antagonist mMRC modified medical research council PsA Pseudomonas aeruginosa RV residual volume 4 Shafiek H et al BMJ Open Resp Res 20218e001067 doi101136bmjresp2021001067 Table 2 Multivariate Cox regression analysis predictors acquiring PSA infection Age Basal mMRC dyspnoea scale FEV1 predicted Systemic corticosteroids use ICS use ICS dose B 0025 0340 0182 0254 0499 0232 SE 0081 0112 0088 0187 0433 0113 Df 1 1 1 1 1 1 Sig 0758 0002 0038 0175 0249 0040 HR 103 141 083 078 061 126 Open access 95 CI HR Lower Upper 088 113 070 054 026 101 120 175 099 112 142 157 Significant p005 Systemic corticosteroids use3 courses follow duration 20122020 Fluticasone propionate equivalents daily dose FEV1 forced expiratory volume 1 s ICS inhaled corticosteroids mMRC modified medical research council PsA Pseudomonas aeruginosa Patients COPD higher daily ICS dose use ICS 133 hazard mortality multivariate cox regression analysis 95 CI 107 165 p001 table 3 adjusted age mMRC dyspnoea scale FEV1 predicted measure airway obstruction severity The use ICS protec tive trend mortality reach statistical significance HR055 p0172 table 3 Both PsA infection higher mMRC dyspnoea scale additional hazard factors mortality p005 Further BEC 300 cellsuL protective factor mortality HR 071 95 CI 052 099 p004 Kaplan Meier survival analysis showed high dose ICS associated significant worse survival 25 vs 50 compared low medium ICS dose users p0001 figure 2 DISCUSSION Severe ExCOPD frequently infected PsA point natural course disease ExCOPD Figure 1 Hazard function analysis dose ICS relation acquiring PsA infection ICS inhaled corticosteroids PsA Pseudomonas aeruginosa commonly treated ICS shown presence PsA sputum marker severity mortality In attempt demonstrate association PsA ICS use higher dose ICS independent risk factor PsA infec tion use Moreover patients continued use high daily dose ICS worse survival compared low medium ICS dose Meanwhile use ICS associated poorer survival fact protective factor mortality multivariate analysis Previous studies Almagro et al 16 AECOPD admis sions caused PsA infection PsA infection significantly related posthospitalisation mortality 3 years19 Similarly Eklöf et al PsA strong independent risk factor causes death AECOPD admissions cause subsequent hospitalisation 2 years follow patients COPD12 Further Jacobs et al outpatient COPD PsA isolation lower FEV1 predicted higher risk mortality compared negative PsA group20 Ni et al meta analysis coexistence COPD bronchiec tasis associated higher rate PsA infection21 Martínez García et al severe exacerbations severe airway obstruction risk factors PsA isolation COPD cohort persistent PsA infection related presence bronchiectasis severe persistent exacerbation associated increased mortality22 Our results agree studies COPD population PsA severe airway obstruction frequent exacerbations higher mortality higher frequency associated bronchiec tasis We PsA infection risk factor mortality multivariate analysis important factor explaining higher mortality COPD PsA population Further low Shafiek H et al BMJ Open Resp Res 20218e001067 doi101136bmjresp2021001067 5 Open access Table 3 Multivariate Cox regression analysis predictors mortality COPD population Age Basal mMRC dyspnoea scale FEV1 predicted Pseudomonas aeruginosa infection Blood eosinophils 300 cellsuL ICS use ICS dose B 0088 0348 0097 0464 0340 0593 0283 SE 0077 0102 0081 0165 0166 0435 0110 Df Sig 1 1 1 1 1 1 1 0253 0001 0231 0005 0040 0172 0010 HR 109 142 091 159 071 055 133 95 CI HR Lower Upper 094 116 078 115 052 024 107 127 173 106 220 099 130 165 Significant p005 Fluticasone propionate equivalents daily dose COPD chronic obstructive pulmonary disease FEV1 forced expiratory volume 1 s ICS inhaled corticosteroids mMRC modified medical research council lung function expressed FEV1 predicted risk factor acquiring PsA infection accordance Martínez García et al22 Interpretation results Frequent antibiotic oral corticosteroid courses commonly management AECOPD13 cause microbiota modification leads isolation PsA20 ICS recommended management ExCOPD13 controversies present prescrip tion ICS stable COPD ICS use linked increased risk pneumonia previous studies15 23 Interestingly current analysis ICS use ICS type use systemic corticosteroids AECOPD risk factor associ ated PsA infection Conversely use ICS showed protective trend mortality studied ExCOPD population Additionally ICS use associated increased risk pneumonia high dose ICS weak risk factor development pneumonia HR112 In line results Garcia Vidal et al relation use ICS PsA infection COPD cohort8 However ICS use linked increased risk pneumonia previous studies15 23 especially use fluticasone propionate compared budesonide24 25 Martinez Garcia et al ICS increased risk pneumonia patients COPD low BEC 100uL associated chronic bronchial infection26 We association use ICS BEC severe COPD population BEC 300 cellsuL protective mortality Yang Yang increased blood eosinophils associated decreased mortality severe AECOPD27 In addition high dose ICS strong independent risk factor acquiring PsA infection adjustment use systemic corticosteroids mortality This explained basis ICS use especially high doses associated change local airway defence mechanisms including T cells alveolar macrophages signalling cyto kines16 2830 Garcha et al airway bacterial load stable COPD related higher dose ICS use30 Similarly Contoli et al 1 year high dose flut icasone propionate use stable COPD associ ated significant increase sputum total bacterial load specially referred Streptococcus pneumoniae Haemophilus influenzae16 Further Håkansson et al bronchiectasis patients PsA isolation frequent ICS higher ICS dose associated mortality31 Figure 2 Kaplan Meier survival analysis according dose ICS patients COPD study 20122020 log rank16811 p0001 COPD chronic obstructive pulmonary disease ICS inhaled corticosteroids Clinical implications Our data reinforce concept use ICS ExCOPD benefit regardless infectious aetiology based improvement survival 6 Shafiek H et al BMJ Open Resp Res 20218e001067 doi101136bmjresp2021001067 In addition data discourage use high doses ICS ExCOPD directly linked increased risk PsA infection mortality Current guidelines recommend use lowest effective ICS dose32 33 consider benefitrisk balance initiating ICS prescription Previous reviews showed relatively flat dose response curve ICS clinical response steep dose response ICS effects34 35 Both Informing Pathway COPD Treatment IMPACT study36 TRIBUTE study37 low medium doses ICS significant reduction moderate severe AECOPD increased risk pneumonia 52 weeks therapy Interestingly line data recent study Eklöf et al ICS risk factor acquiring PsA infection dose dependent risk compared ICS severe COPD Danish cohort38 Limitations The current study limitations First study underlying mechanisms increasing mortality COPD PsA population ICS However increased airway inflammation caused PsA high virulence terms biofilm formation resistance airway mediated clearance mechanism possible mechanisms ExCOPD patients3941 Second overlap airway colonisation new airway infection present analyse separately chronic bronchial infection However lower airways bacterial colonisation associated frequent AECOPD modulate characteristics exacerbation42 Lastly ordinary microbio logical culture quantitative PCR bacterial detection current study Microbiological detection airways molecular techniques accurate discriminatory30 costly available centres To knowledge casecontrol study longitudinal follow demonstrates ICS use ICS dose associated PsA infection frequent exacerbator COPD patients CONCLUSIONS ICS dose important risk factor PsA infec tion ExCOPD use Further high ICS dose independent risk factor mortality Moreover PsA infection important risk factor mortality patients However studies required evaluate relationship ICS PsA infection patients ith COPD Contributors HS NT P acquisition data analysis interpretation data statistical analysis drafting manuscript JV LR C recruitment patients acquisition data interpretation data drafting manuscript AI CL C CJ PF R AO sputum analysis microbiological evaluation data analysis interpretation data critical revision manuscript BGC conception design research analysis interpretation data supervision work drafting manuscript critical revision manuscript important intellectual content Open access Funding The project partly funded non restricted grant Menarini HS funded scholarship ID 20192020 Ministry Higher Education Arab Republic Egypt Competing interests None declared Patient consent publication Not applicable Ethics approval The study approved ethical committee Islas Baleares Ref IB 3537 17 Provenance peer review Not commissioned externally peer reviewed Data availability statement Data available reasonable request All data relevant study included article uploaded online supplemental information All data relevant study included article associated supplemental material datasets included available reasonable request The current study clinical trial Supplemental material This content supplied authors It vetted BMJ Publishing Group Limited BMJ peer reviewed Any opinions recommendations discussed solely authors endorsed BMJ BMJ disclaims liability responsibility arising reliance placed content Where content includes translated material BMJ warrant accuracy reliability translations including limited local regulations clinical guidelines terminology drug names drug dosages responsible error andor omissions arising translation adaptation Open access This open access article distributed accordance Creative Commons Attribution Non Commercial CC BY NC 40 license permits distribute remix adapt build work non commercially license derivative works different terms provided original work properly cited appropriate credit given changes indicated use non commercial See httpcreativecommonsorglicensesbync40 ORCID iD Borja G Cosio httporcidorg0000000263888209 REFERENCES 1 Vestbo J Edwards LD Scanlon PD et al Changes forced expiratory volume 1 second time COPD N Engl J Med 2011365118492 2 Suissa S DellAniello S Ernst P Long Term natural history chronic obstructive pulmonary disease severe exacerbations mortality Thorax 20126795763 3 Fagon JY Chastre J Trouillet JL et al Characterization distal bronchial microflora acute exacerbation chronic bronchitis Use protected specimen brush technique 54 mechanically ventilated patients Am Rev Respir Dis 199014210048 4 Monsó E Ruiz J Rosell A et al Bacterial infection chronic obstructive pulmonary disease A study stable exacerbated outpatients protected specimen brush Am J Respir Crit Care Med 1995152131620 5 Moghoofei M Azimzadeh Jamalkandi S Moein M et al Bacterial infections acute exacerbation chronic obstructive pulmonary disease systematic review meta analysis Infection 2020481935 6 Bogaert D van der Valk P Ramdin R et al Host Pathogen interaction pneumococcal infection patients chronic obstructive pulmonary disease Infect Immun 20047281823 7 Soler N Torres A Ewig S et al Bronchial microbial patterns severe exacerbations chronic obstructive pulmonary disease COPD requiring mechanical ventilation Am J Respir Crit Care Med 19981571498505 8 Garcia Vidal C Almagro P Romaní V et al Pseudomonas aeruginosa patients hospitalised COPD exacerbation prospective study Eur Respir J 20093410728 9 Lode H Allewelt M Balk S et al A prediction model bacterial etiology acute exacerbations COPD Infection 2007351439 10 Cosío BG Shafiek H Verdú J et al Implementation integrated care model Frequent Exacerbator COPD patients controlled prospective study Arch Bronconeumol 2021 doi101016j arbres202101025 Epub ahead print 13 Feb 2021 11 Hill AT Campbell EJ Hill SL et al Association airway bacterial load markers airway inflammation patients stable chronic bronchitis Am J Med 200010928895 12 Eklöf J Sørensen R Ingebrigtsen TS et al Pseudomonas aeruginosa risk death exacerbations patients chronic obstructive pulmonary disease observational cohort study 22 053 patients Clin Microbiol Infect 20202622734 Shafiek H et al BMJ Open Resp Res 20218e001067 doi101136bmjresp2021001067 7 Open access 13 Vogelmeier CF Criner GJ Martinez FJ et al Global strategy diagnosis management Prevention Chronic Obstructive Lung Disease 2017 Report GOLD Executive Summary Arch Bronconeumol 20175312849 14 Miravitlles M Calle M Molina J et al Spanish COPD guidelines GesEPOC 2021 updated pharmacological treatment stable COPD Arch Bronconeumol 2021 doi101016jarbr202103014 Epub ahead print 17 Mar 2021 15 Crim C Calverley PMA Anderson JA et al Pneumonia risk COPD patients receiving inhaled corticosteroids combination torch study results Eur Respir J 2009346417 16 Contoli M Pauletti A Rossi MR et al Long Term effects inhaled corticosteroids sputum bacterial viral loads COPD Eur Respir J 2017501700451 pulmonary disease retrospective cohort study Int J Chron Obstruct Pulmon Dis 2021162818 28 Suissa S Patenaude V Lapi F et al Inhaled corticosteroids COPD risk pneumonia Thorax 201368102936 29 Brassard P Suissa S Kezouh A et al Inhaled corticosteroids risk tuberculosis patients respiratory diseases Am J Respir Crit Care Med 20111836758 30 Garcha DS Thurston SJ Patel ARC et al Changes prevalence load airway bacteria quantitative PCR stable exacerbated COPD Thorax 201267107580 31 Håkansson KEJ Fjaellegaard K Browatzki A et al Inhaled corticosteroid therapy bronchiectasis associated cause mortality prospective cohort study Int J Chron Obstruct Pulmon Dis 202116211927 17 National Institute Health Care Excellence Inhaled 32 Soler Cataluña JJ Piñera P Trigueros JA et al Spanish COPD corticosteroid doses NICEs asthma guideline NICE Guideline NG80 2018 Available httpniceorgukguidelinesNG80 18 Murray PR Washington JA Microscopic baceriologic analysis expectorated sputum Mayo Clin Proc 19755033944 19 Almagro P Salvadó M Garcia Vidal C et al Pseudomonas aeruginosa mortality hospital admission chronic obstructive pulmonary disease Respiration 2012843643 20 Jacobs DM Ochs Balcom HM Noyes K et al Impact Pseudomonas aeruginosa Isolation Mortality Outcomes Outpatient Chronic Obstructive Pulmonary Disease Cohort Open Forum Infect Dis 20207ofz546 guidelines GesEPOC 2021 update diagnosis treatment AF COPD exacerbation syndrome Arch Bronconeumol 2021 doi101016jarbres202105011 Epub ahead print 26 May 2021 33 la Rosa Carrillo D López Campos JL Alcázar Navarrete B et al Consensus document diagnosis treatment chronic bronchial infection chronic obstructive pulmonary disease Arch Bronconeumol 20205665164 34 Lipworth BJ Airway systemic effects inhaled corticosteroids asthma dose response relationship Pulm Pharmacol 199691927 21 Ni Y Shi G Yu Y et al Clinical characteristics patients 35 Kankaanranta H Lahdensuo A Moilanen E et al Add On chronic obstructive pulmonary disease comorbid bronchiectasis systemic review meta analysis Int J Chron Obstruct Pulmon Dis 201510146575 22 Martínez García Miguel Ángel Faner R Oscullo G et al Risk Factors Relation Mortality New Acquisition Persistence Pseudomonas aeruginosa COPD Patients COPD 20211833340 23 Festic E Bansal V Gupta E et al Association inhaled corticosteroids incident pneumonia mortality COPD patients Systematic Review Meta Analysis COPD 20161331226 24 Lodise TP Li J Gandhi HN et al Intraclass difference pneumonia risk fluticasone budesonide COPD systematic review evidence Direct Comparison studies Int J Chron Obstruct Pulmon Dis 2020152889900 25 Yang M Du Y Chen H et al Inhaled corticosteroids risk pneumonia patients chronic obstructive pulmonary disease meta analysis randomized controlled trials Int Immunopharmacol 201977105950 therapy options asthma adequately controlled inhaled corticosteroids comprehensive review Respir Res 2004517 36 Lipson DA Barnhart F Brealey N et al Once Daily Single Inhaler triple versus dual therapy patients COPD N Engl J Med 2018378167180 37 Papi A Vestbo J Fabbri L et al Extrafine inhaled triple therapy versus dual bronchodilator therapy chronic obstructive pulmonary disease tribute double blind parallel group randomised controlled trial Lancet 2018391107684 38 Eklöf J Ingebrigtsen TS Sørensen R et al Use inhaled corticosteroids risk acquiring Pseudomonas aeruginosa patients chronic obstructive pulmonary disease Thorax 2021 doi101136thoraxjnl2021217160 Epub ahead print 26 Aug 2021 39 Donaldson GC Seemungal TAR Bhowmik A et al Relationship exacerbation frequency lung function decline chronic obstructive pulmonary disease Thorax 20025784752 40 Cullen L McClean S Bacterial adaptation chronic respiratory infections Pathogens 201546689 26 Martinez Garcia MA Faner R Oscullo G et al Inhaled steroids circulating eosinophils chronic airway infection pneumonia risk chronic obstructive pulmonary disease A network analysis Am J Respir Crit Care Med 2020201107885 41 Riquelme SA Ahn D Prince A Pseudomonas aeruginosa Klebsiella pneumoniae adaptation innate immune clearance mechanisms lung J Innate Immun 20181044254 42 Patel IS Seemungal TAR Wilks M et al Relationship 27 Yang J Yang J Association blood eosinophils mortality critically ill patients acute exacerbation chronic obstructive bacterial colonisation frequency character severity COPD exacerbations Thorax 20025775964 8 Shafiek H et al BMJ Open Resp Res 20218e001067 doi101136bmjresp2021001067